CriticalSelective serotonin 5HT1B/1D agonists (triptans)×Selective irreversible MAO-B inhibitor
Updated · Methodology
Mechanism
At recommended doses, selegiline inhibits monoamine oxidase type B (MAO-B) selectively and irreversibly, and above 10 mg a day it may lose this selectivity (selegiline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4, 5.1 and 5.2). Almotriptan is a selective agonist of serotonin 5-HT1B and 5-HT1D receptors, and its main metabolic route is oxidative deamination by monoamine oxidase type A (almotriptan SmPC, AEMPS, sections 5.1 and 5.2). The selegiline SmPC contraindicates selegiline with serotonin agonists because of the risk of serious interactions that can lead to serotonin syndrome. Almotriptan is not among the examples, but its own SmPC places it in this class (selegiline SmPC, AEMPS, section 4.5). The Spanish almotriptan SmPC itself does not rule out serotonin syndrome due to a pharmacodynamic interaction with monoamine oxidase inhibitors (almotriptan SmPC, AEMPS, section 4.5). The documents contain no studies of almotriptan with selegiline. The monoamine oxidase type A inhibitor moclobemide reduced almotriptan clearance by 27%, and the US label says no dose adjustment is needed (almotriptan label, US Food and Drug Administration, FDA, section 12.3).
Symptoms
The documents do not describe how this particular combination presents, but the selegiline summary of product characteristics (SmPC) warns that serious interactions with serotonin agonists can lead to serotonin syndrome (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). According to the US Food and Drug Administration (FDA) almotriptan label, serotonin syndrome can be life-threatening, and its signs include mental status changes (agitation, hallucinations, coma), autonomic instability (fast heart rate, labile blood pressure, high temperature), neuromuscular changes (overactive reflexes, poor coordination), nausea, vomiting and diarrhoea (FDA almotriptan label, section 5.5). Almotriptan itself can cause a transient, moderate rise in blood pressure, more marked in older people, and chest pain and tightness, sometimes intense and spreading to the throat (almotriptan SmPC, AEMPS, section 4.4). On rare occasions, like other triptans, it has caused significant rises in blood pressure, including in people with no history of hypertension (FDA almotriptan label, section 5.7). Above the recommended 10 mg a day, selegiline may lose its selectivity for monoamine oxidase type B (MAO-B), which raises the risk of hypertension (selegiline SmPC, AEMPS, section 4.4).
Management
The combination is contraindicated: do not prescribe almotriptan to people taking selegiline. The selegiline summary of product characteristics (SmPC) lists serotonin agonists among contraindicated combinations (Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). Almotriptan is not among the examples in that sentence, but its own SmPC describes it as a selective agonist of serotonin 5-HT1B and 5-HT1D receptors (almotriptan SmPC, AEMPS, section 5.1), so the class contraindication applies to it as well. The almotriptan documents are softer, but this does not lift the contraindication in the selegiline SmPC. The Spanish almotriptan SmPC only says that serotonin syndrome with monoamine oxidase inhibitors cannot be ruled out (almotriptan SmPC, AEMPS, section 4.5). The US Food and Drug Administration (FDA) label does not list monoamine oxidase inhibitors among its contraindications (FDA almotriptan label, section 4). No document gives an interval between stopping selegiline and the first dose of almotriptan, or for the opposite switch. Selegiline inhibits monoamine oxidase type B (MAO-B) irreversibly, and after a single 10 mg dose platelet MAO-B activity returns to normal in about 2 weeks (selegiline SmPC, AEMPS, section 5.2). Almotriptan is also contraindicated on its own in severe hypertension and in uncontrolled mild or moderate hypertension (almotriptan SmPC, AEMPS, section 4.3). If chest pain or tightness suggesting cardiac ischaemia appears after almotriptan, withhold further doses and assess the patient (almotriptan SmPC, AEMPS, section 4.4).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Almotriptan tablets (Ajanta Pharma USA) – prescribing information (2025)– FDA label, Ajanta Pharma USA, DailyMed setid 6fa380c4-c885-4743-85bf-88819ae68645, version 10, 12/2025, sections 4.5, 7.1 and 12.3
- AEMPS: Ficha técnica: Selegilina, Plurimen 5 mg (nº registro 58113) (2026)– AEMPS, CIMA, nº registro 58113 (Plurimen 5 mg comprimidos), revisión 03/2026, secciones 4.3, 4.4, 4.5 y 5.1
- AEMPS: Ficha técnica: Almotriptán (nº registro 62877), sección 4.3 (2021)– AEMPS, CIMA, nº registro 62877, revisión 02/2021, secciones 4.3 y 4.4
- AEMPS: Ficha técnica: Almotriptán (nº registro 62877), sección 4.5 (2021)– AEMPS, CIMA, nº registro 62877 (Almogran 12,5 mg, Almirall), revisión 02/2021, secciones 4.4, 4.5, 5.1 y 5.2